ArticleBioconjugate chemistry2011
Surface functionalization of virus-like particles by direct conjugation using azide-alkyne click chemistry.
Article in Bioconjugate chemistry, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 73 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
73 citing papers in PubMed, 176 citations in OpenAlex.
- Metabolic Engineering and Bioprocess Optimization Strategies Promote l‑Azidohomoalanine Biosynthesis in Fed-Batch Bioreactor Culture.ACS omega · 2026Article
- Virus-like particles in cancer immunotherapy: bridging human and veterinary medicine through one health.Journal of nanobiotechnology · 2026Review
- Review
- Engineering strategies and decision frameworks for virus-like particle-based vaccines against infectious diseases.Frontiers in microbiology · 2026Review
- Immunogenicity and efficacy of an mRNA vaccine expressing a virus-like particle spike antigen against SARS-CoV-2.NPJ vaccines · 2025Article
- mRNA therapeutics: Transforming medicine through innovation in design, delivery, and disease treatment.Molecular therapy. Nucleic acids · 2025Review
- Impact of specific productivity and operation mode upon the biophysical properties of HIV-1 Gag-based virus-like particles.Applied microbiology and biotechnology · 2025Article
- Advances in the Functionalization of Vaccine Delivery Systems: Innovative Strategies and Translational Perspectives.Pharmaceutics · 2025Review
- Breaking barriers: Smart vaccine platforms for cancer immunomodulation.Cancer communications (London, England) · 2025Review
- Ferritin Vaccine Platform for Animal and Zoonotic Viruses.Vaccines · 2024Review
- Tailored Viral-like Particles as Drivers of Medical Breakthroughs.International journal of molecular sciences · 2024Review
- Rapid Generation of Therapeutic Nanoparticles Using Cell-Free Expression Systems.Small methods · 2023Article
- Preparation and Biological Properties of Oligonucleotide-Functionalized Virus-like Particles.Biomacromolecules · 2023Article
- Ferritin nanocages as efficient nanocarriers and promising platforms for COVID-19 and other vaccines development.Biochimica et biophysica acta. General subjects · 2023Review
- Quantitative functionalization of biosynthetic caged protein materials.Quantitative biology (Beijing, China) · 2023Review
- Virus-like Particles for TEM Regulation and Antitumor Therapy.Journal of functional biomaterials · 2022Review
- Nanoparticle-Based Delivery Systems for Vaccines.Vaccines · 2022Review
- Addition of LauryldimethylamineACS omega · 2022Article
- Virus-like Particles as Nanocarriers for Intracellular Delivery of Biomolecules and Compounds.Viruses · 2022Review
- Current advances and challenges in COVID-19 vaccine development: from conventional vaccines to next-generation vaccine platforms.Molecular biology reports · 2022Review
13 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
We present a cell-free protein synthesis (CFPS) platform and a one-step, direct conjugation scheme for producing virus-like particle (VLP) assemblies that display multiple ligands including proteins, nucleic acids, and other molecules. Using a global methionine replacement approach, we produced bacteriophage MS2 and bacteriophage Qβ VLPs with surface-exposed methionine analogues (azidohomoalanine and homopropargylglycine) containing azide and alkyne side chains. CFPS enabled the production of VLPs with yields of ~ 300 μg/mL and with 85% incorporation of methionine analogues without requiring a methionine auxotrophic production host. We then directly conjugated azide- and alkyne-containing proteins (including an antibody fragment and the granulocyte-macrophage colony stimulating factor, or GM-CSF), nucleic acids and poly(ethylene glycol) chains to the VLP surface using Cu(I) catalyzed click chemistry. The GM-CSF protein, after conjugation to VLPs, was shown to partially retain its ability to stimulate the proliferation of cells. Conjugation of GM-CSF to VLPs resulted in a 3-5-fold reduction in its bioactivity. The direct attachment scheme facilitated conjugation of three different ligands to the VLPs in a single step, and enabled control of the relative ratios and surface abundance of the attached species. This platform can be used for the production of novel VLP bioconjugates for use as drug delivery vehicles, diagnostics, and vaccines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.